نتایج جستجو برای: bisphosphonates

تعداد نتایج: 3632  

2014
Deting Xue Fangcai Li Gang Chen Shigui Yan Zhijun Pan

BACKGROUND Whether bisphosphonates affect indirect bone healing is still unclear. METHOD We carried out a comprehensive search strategy. Only randomized controlled trials were included. Two reviewers independently assessed methodological qualities and extracted outcome data. Analysis was performed with RevMan 5.2. RESULTS Eight eligible randomized controlled trials with 2,508 patients were ...

2010
Yonghui Zhang Rong Cao Fenglin Yin Fu-Yang Lin Hong Wang Kilannin Krysiak Joo-Hwan No Dushyant Mukkamala Kevin Houlihan Jikun Li Craig T. Morita Eric Oldfield

Bisphosphonates such as risedronate and ibandronate are widely used to treat a variety of bone resorption diseases, preventing protein prenylation and disrupting osteoclast function. Bisphosphonates also activate human gd T cells (expressing the Vg2Vd2 T cell receptor), and these activated gd T cells kill tumor cells. 3] There has thus been interest in using bisphosphonates in cancer immunother...

Journal: :Cancer control : journal of the Moffitt Cancer Center 1999
Cristofanilli Hortobagyi

BACKGROUND: Bone is the most frequent site of metastasis in patients with breast cancer. Bone metastasis, particularly osteolytic bone destruction, is usually associated with significant morbidity and deterioration of quality of life. Bisphosphonates are specific inhibitors of osteoclast activity used in the treatment of hypercalcemia of malignancy and osteolytic bone disease. METHODS: We revie...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2016
P Hadji R E Coleman C Wilson T J Powles P Clézardin M Aapro L Costa J-J Body C Markopoulos D Santini I Diel A Di Leo D Cameron D Dodwell I Smith M Gnant R Gray N Harbeck B Thurlimann M Untch J Cortes M Martin U-S Albert P-F Conte B Ejlertsen J Bergh M Kaufmann I Holen

Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss (CTIBL) and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do not currently have regulatory approval for either of these potential indications. This consensus paper provides a rev...

Journal: :Clinical advances in hematology & oncology : H&O 2011
Rebecca Aft

Bone metastases add to the burden of breast cancer, with patients experiencing severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy. Nitrogen-containing bisphosphonates have become the standard treatment for skeletal-related events and bone pain, as well as for bone loss associated with chemotherapy and aromatase inhibitors. Emerging preclinical and c...

2012
Dong Yeob Shin Cheol Ryong Ku Kyung Min Kim Han Seok Choi Yumie Rhee Eun Jig Lee Sung-Kil Lim

Bisphosphonates are potent inhibitors of bone resorption and widely used to treat osteoporosis. Extensive studies have shown that therapy with bisphosphonates improves bone density and decreases fracture risk. However, concerns have been raised about potential over-suppression of bone turnover during long-term use of bisphosphonates, resulting in increased susceptibility to and delayed healing ...

2015
Xinyu Zhao Dongcai Hu Jun Qin Rahul Mohanan Liaobin Chen

BACKGROUND Bone loss leading to aseptic loosening of the prosthesis and periprosthetic fracture is a mode of failure in cementless total hip arthroplasty (THA). The aim of this meta-analysis was to evaluate the effect of bisphosphonates in preventing femoral periprosthetic bone resorption following primary cementless THA zone by zone. METHOD Clinical randomized controlled trials concerning bi...

2011
Maurizio Muratore Eugenio Quarta Antonella Grimaldi Fabio Calcagnile Laura Quarta

Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into...

Journal: :Forum Médical Suisse ‒ Swiss Medical Forum 2012

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید